in DoD facilities and the Centers for Disease Control and Prevention's Laboratory Response Network.
The DoD and its partners accelerated a vaccine candidate [2] from a longstanding project to produce a trivalent vaccine against Ebola, Marburg, and Sudan viruses, provided 50 000 doses for clinical trials, and accelerated treatment candidates that offer a spectrum of therapeutic strategies: viral neutralization via monoclonal antibodies (ZMapp), small molecule antagonism of a viral enzyme (favipiravir), and RNA interference (TKM-100802) [3] [4] [5] [6] .
The DoD conducted preclinical and clinical research at the US Army Medical Research Institute of Infectious Diseases and the Walter Reed Army Institute of Research, respectively. Dr Schooley emphasizes the need to standardize reagents, assays, and controls for animal models; DoD, interagency, academic, and international partners coordinate these efforts through the Filovirus Animal Model Nonclinical Group [6] . Dr Schooley notes that decreasing incidence rates may preclude evaluation of efficacy in clinical trials [7] [8] [9] during this outbreak; we agree that developing local capacities and coordinating product developers, host-nation ministries of health, and institutional review boards are essential to proactively establish clinical trial sites and pre-position study protocols to expedite evaluation and fielding of medical countermeasures, in addition to continued research in accordance with the FDA's Animal Rule.
The DoD supports the US Wholeof-Government response in coordination with the National Institutes of Health and other organizations within the Department of Health and Human Services, and in partnership with industry and academia [6] . The fact that no countermeasures had attained regulatory approval before the start of this outbreak is an obvious disappointment in the face of a public health disaster. However, years of prior research built the foundation for the acceleration of 6 candidates from preclinical or early clinical development to Emergency Use Authorizations and clinical trials within months of the epidemic's discovery, unprecedented in outbreaks of other emerging pathogens including highly pathogenic avian influenza, novel zoonotic coronaviruses, and Nipah virus. By accelerating candidates toward regulatory approval, the DoD is positioned to offer diagnostics, vaccines, and treatments generated by its biological defense program. Coordination of biological defense and public health response is vital to optimize outcomes and maximize efficient utilization of resources, and because the challenges posed by both biological weapons and emerging diseases are open-ended [10] . 
